Evidence map›Paper›PMID 18802485›Full record

ArticleThe Journal of clinical investigation2008

Novel epitope begets a novel pathway in type 1 diabetes progression.

Jeffrey A Frelinger

Open access · bronzeAbstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jeffrey A FrelingerDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina 27599-7290, USA. jfrelin@med.unc.edu
University of North Carolina at Chapel Hill · US

Funding

Targeting CD8+ T Cell to Prevent B Cell DestructionR01AI052435 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FRELINGER, JEFFREY ALLEN · 2003 to 2010
$2.1M
Defining Antigen Induced Immunoregulation in T1 DiabetesR01AI058014 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TISCH, ROLAND M · 2004 to 2008
$1.8M
NIAID NIH HHS AI058014NIAID NIH HHS AI52435NIAID NIH HHS R01 AI052435NIAID NIH HHS R01 AI058014
6 · The paper itself

Abstract

While CD8+ T cells are critical to diabetogenesis in NOD mice, evidence of their involvement in human type 1 diabetes (T1D) has been circumstantial. The existence of CD8+ T cells specific for beta cell peptides has been demonstrated, but functional data regarding the role of these cells in T1D have been lacking. In this issue of the JCI, Skowera et al. describe an unusual self-peptide epitope derived from the leader sequence of preproinsulin (PPI) and show that 50% of HLA-A2+ patients with new-onset T1D possessed circulating CD8+ T cells specific for this epitope, suggesting that PPI plays a critical role in the development of T1D (see the related article beginning on page 3390). They also report that beta cells upregulate PPI expression in the presence of high glucose levels, rendering these cells more susceptible to lysis and potentially accelerating disease. This suggests that interventions aimed at decreasing the PPI-specific CD8+ T cell response early after T1D diagnosis may be efficacious in ameliorating the disease process.

Indexed as

AnimalsCD8-Positive T-LymphocytesDiabetes Mellitus, Type 1Disease ProgressionEpitopes, T-LymphocyteHumansInsulinInsulin-Secreting CellsMiceMice, Inbred NODProtein PrecursorsEpitopes, T-LymphocyteInsulinpreproinsulinProtein Precursors

Identifiers

PMID18802485
PMCPMC2542855
OpenAlexW1980037426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.